Post by Rebrain.

🚀 𝗙𝗜𝗥𝗦𝗧 𝗣𝗔𝗧𝗜𝗘𝗡𝗧 𝗧𝗥𝗘𝗔𝗧𝗘𝗗 — 𝗢𝗣𝗧𝗜𝗥𝗦 𝗜𝗦 𝗡𝗢𝗪 𝗟𝗜𝗩𝗘   A major milestone was achieved for the OPTIRS (𝘖𝘱𝘵𝘪𝘮𝘪𝘻𝘪𝘯𝘨 𝘝𝘐𝘔 𝘵𝘢𝘳𝘨𝘦𝘵𝘪𝘯𝘨 𝘧𝘰𝘳 𝘳𝘢𝘥𝘪𝘰𝘴𝘶𝘳𝘨𝘦𝘳𝘺 𝘪𝘯 𝘴𝘦𝘷𝘦𝘳𝘦 𝘵𝘳𝘦𝘮𝘰𝘳) study, led by 𝗣𝗿 𝗝𝗲𝗮𝗻 𝗥𝗲́𝗴𝗶𝘀 at APHM (Assistance Publique - Hopitaux de Marseille): 𝗧𝗵𝗲 𝗳𝗶𝗿𝘀𝘁 𝗽𝗮𝘁𝗶𝗲𝗻𝘁 𝘄𝗮𝘀 𝗼𝗳𝗳𝗶𝗰𝗶𝗮𝗹𝗹𝘆 𝗶𝗻𝗰𝗹𝘂𝗱𝗲𝗱 𝗮𝗻𝗱 𝘁𝗿𝗲𝗮𝘁𝗲𝗱 𝗼𝗻 𝗝𝘂𝗻𝗲 𝟭𝟭, 𝟮𝟬𝟮𝟲.   This prospective, randomized controlled clinical trial compares standard targeting with our 𝗱𝗮𝘁𝗮-𝗮𝘀𝘀𝗶𝘀𝘁𝗲𝗱 𝘁𝗮𝗿𝗴𝗲𝘁𝗶𝗻𝗴 in functional radiosurgery for severe tremor (40 patients, 1:1 randomization). The technology is already 𝗙𝗗𝗔-𝗰𝗹𝗲𝗮𝗿𝗲𝗱 𝗮𝗻𝗱 𝗖𝗘-𝗺𝗮𝗿𝗸𝗲𝗱. The study aims to demonstrate 𝗮𝗽𝗽𝗹𝗶𝗰𝗮𝗯𝗶𝗹𝗶𝘁𝘆 𝗮𝗰𝗿𝗼𝘀𝘀 𝘁𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝗶𝗲𝘀 𝗮𝗻𝗱 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘀𝗲𝘁𝘁𝗶𝗻𝗴𝘀, reinforcing the scalability of our service. In addition to clinical outcomes, it will assess 𝘄𝗼𝗿𝗸𝗳𝗹𝗼𝘄 𝗲𝗳𝗳𝗶𝗰𝗶𝗲𝗻𝗰𝘆 𝗮𝗻𝗱 𝗵𝗲𝗮𝗹𝘁𝗵-𝗲𝗰𝗼𝗻𝗼𝗺𝗶𝗰 𝗶𝗺𝗽𝗮𝗰𝘁, complementing evidence from other Rebrain clinical programs.   This trial marks a 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗰 𝘀𝘁𝗲𝗽 for Rebrain, supporting adoption, reimbursement discussions, and the expansion of our technology across multiple functional neurosurgery modalities.